Skandinaviska Enskilda Banken (SEB)
TGTX icon

Skandinaviska Enskilda Banken (SEB)’s TG Therapeutics TGTX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-75,000
Closed -$1.75M – 863
2024
Q3 		$1.75M Buy
+75,000
New +$1.64M 0.01% 610
2024
Q1 		– Sell
-17,600
Closed -$300K – 941
2023
Q4 		$300K Buy
+17,600
New +$205K ﹤0.01% 812

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s TGTX Position: Q4 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 75,000 shares — an estimated $1.75M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in TGTX in Q4 2023 and held it in 2 quarters. The position peaked at $1.75M in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 75,000 TG Therapeutics shares in Q4 2024, an estimated $1.75M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in TG Therapeutics in Q4 2023 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s TG Therapeutics position peaked at $1.75M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2024, filed 10 Feb 2025.